Allen Larry A, O'Connor Christopher M
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
CMAJ. 2007 Mar 13;176(6):797-805. doi: 10.1503/cmaj.051620.
Acute decompensated heart failure represents a heterogeneous group of disorders that typically present as dyspnea, edema and fatigue. Despite the high prevalence of this condition and its associated major morbidity and mortality, diagnosis can be difficult, and optimal treatment remains poorly defined. Identification of the acute triggers for the decompensation as well as noninvasive characterization of cardiac filling pressures and output is central to management. Diuretics, vasodilators, continuous positive airway pressure and inotropes can be used to alleviate symptoms. However, few agents currently available for the treatment of acute decompensated heart failure have been definitively shown in large prospective randomized clinical trials to provide meaningful improvements in intermediate-term clinical outcomes. Multiple novel therapies are being developed, but previous treatment failures indicate that progress in the management of acute decompensated heart failure is likely to be slow.
急性失代偿性心力衰竭是一组异质性疾病,通常表现为呼吸困难、水肿和乏力。尽管这种疾病的患病率很高,且伴有严重的发病率和死亡率,但诊断可能很困难,最佳治疗方案仍不明确。识别失代偿的急性触发因素以及对心脏充盈压和心输出量进行无创性评估是管理的核心。利尿剂、血管扩张剂、持续气道正压通气和强心剂可用于缓解症状。然而,目前用于治疗急性失代偿性心力衰竭的药物中,很少有在大型前瞻性随机临床试验中被明确证明能在中期临床结局方面带来有意义改善的。多种新型疗法正在研发中,但以往的治疗失败表明,急性失代偿性心力衰竭管理方面的进展可能会很缓慢。